SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to ...

SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, ...

(MENAFN- GlobeNewsWire - Nasdaq) SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide SALT LAKE CITY, Nov. 13, 2024 ...

Myriad Genetics (MYGN) continues to empower parents with increased access to prenatal testing. SneakPeek is now available over the counter in more than 8,800 retail locations nationwide. The product ...

SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad ...

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking ...

The global Cell-free fetal DNA testing market is estimated to be valued at USD 1,687.8 million in 2025 and is projected to reach USD 3,051.5 million by 2035, registering a compound annual growth rate ...

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...